Skip to main content

Day: February 18, 2021

GTX Corp Adds Rapid Diagnostic Test Kits for the SARS-COV-2 (COVID-19) Antigen

LOS ANGELES, CALIFORNIA, Feb. 18, 2021 (GLOBE NEWSWIRE) — GTX Corp (OTC: GTXO) (“GTX” or the “Company”), a pioneer in the field of wearable GPS human and asset tracking systems and a supplier of Health and Safety personal protective medical equipment “PPE”, announced today it has begun the distribution of a Rapid Diagnostic Test-Kits for Antigens. The highly accurate, 10-minute results COVID-19 Antigen test is approved under the Emergency Use Authorization (“EAU”) and tests for the detection of Antigens specific to SARS-CoV-2.The COVID-19 Antigen test (www.gtxmask.com) is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in nasopharyngeal swab specimens collected from individuals who are suspected of COVID-19 by their healthcare provider within the first...

Continue reading

ME2C Environmental Eliminates $860,000 of Convertible Debt

Conversion Further Reduces Debt Profile & Fortifies Balance SheetCORSICANA, TX, Feb. 18, 2021 (GLOBE NEWSWIRE) — Midwest Energy Emissions Corp. (OTCQB: MEEC) (“ME2C Environmental” or the “Company”), a leading environmental technologies firm, today announced that the Company will convert holders of all of outstanding principal of its 2018 Convertible Promissory Notes into ME2C Environmental shares. The Company will convert a total of $860,000 of outstanding principal into shares of the Company’s common stock at the Note’s conversion price of $0.50 per share.Richard MacPherson, President and Chief Executive Officer of ME2C Environmental, commented: “We continue to see exciting momentum in the industry in conjunction with several recent announcements. Earlier this month, we announced that we are actively developing...

Continue reading

AgEagle Aerial Systems and The ArcView Group to Co-Host Hemp Town Hall Virtual Event on March 4, 2021

Webinar Will Feature State Regulators and Other Industry Experts Discussing the Future of U.S. HempWICHITA, Kan. and LOS ANGELES, Feb. 18, 2021 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (NYSE American: UAVS) (“AgEagle” or the “Company”), an industry leading drone solutions provider, and The Arcview Group jointly announced that the companies will be co-hosting a virtual town hall event, titled “State Regulators Look at the Future of U.S. Hemp,” on Thursday, March 4, 2021 beginning at 12:00 PM Eastern Time.Webinar participants will hear from several of the country’s state hemp regulatory leaders on a variety of topics, including what steps states are taking to support and accelerate growth of the U.S. Hemp industry. Free to all participants, this must-attend online event will include informative panel discussions and insightful...

Continue reading

Pliant Therapeutics to Participate in Upcoming Virtual Investor Events

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that management will be participating in the following virtual investor events in March:Cowen 41stAnnual Health Care Conference – March 1-4, 2021. Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in the Respiratory/Infections Panel discussion on March 1, 2021 at 10:30 a.m. ET/ 7:30 a.m. PT and, along with members of Pliant’s senior management team, will conduct one-on-one meetings with members of the investment community.The Cowen Respiratory/Infections Panel will stream live and have a replay available on Cowen’s Conference Site.Citi’s...

Continue reading

Albireo to Report Q4 and Year-End 2020 Financial Results on February 25

BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on February 25, 2021, to provide a business update and review the company’s financial results for the fourth quarter and year ended December 31, 2020.To access the live conference call by phone, please dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access code 13715566. A live audio webcast will be accessible from the Media & Investors page of Albireo’s website, https://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the start time. An archived...

Continue reading

OrthoPediatrics Corp. Launches Dedicated ApiFix Website to Support Game-Changing Spinal Deformity Correction System for Treating AIS

WARSAW, Ind., Feb. 18, 2021 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics and which has expanded its operating reach over the last year to serve more children around the world, today announced the launch of APIFIX.COM, a new online presence aimed at informing patients, families and healthcare providers of a viable new alternative for the treatment of progressive adolescent idiopathic scoliosis (AIS).“Growing our online presence is one of many ways we are elevating the importance of offering a viable new option for patients and surgeons to consider when treating adolescent idiopathic scoliosis,” said Ryan Bledsoe, Director of Product Management at OrthoPediatrics. “The new website includes actionable information...

Continue reading

InterDigital Reports Fourth Quarter and Full Year 2020 Financial Results

WILMINGTON, Del., Feb. 18, 2021 (GLOBE NEWSWIRE) — InterDigital, Inc. (NASDAQ:IDCC), a mobile and video technology research and development company, today announced results for the fourth quarter and full year ended December 31, 2020.Fourth Quarter 2020 Financial HighlightsRecurring revenue was $89.1 million, compared to $77.5 million in fourth quarter 2019, a 15% year-over-year increase, which was driven by six new patent license agreements signed during 2020. Total revenue was $90.8 million, compared to $102.2 million in fourth quarter 2019, which is attributable to past sales from deals signed in fourth quarter 2019.Operating expenses were $87.7 million, compared to $76.9 million in fourth quarter 2019, due to one-time charges of approximately $10.0 million, primarily related to a non-cash charge for on-going patent portfolio...

Continue reading

Allogene Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time/5:00 PM Eastern Time.Audio WebcastThe webcast will be made available on the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company’s website for approximately 30 days.Dial-In InformationLive (U.S. / Canada): 1 (866) 940-5062Live (International):...

Continue reading

Global Diversified Marketing Group Reports Record Revenue Growth for 2020

ISLAND PARK, N.Y., Feb. 18, 2021 (GLOBE NEWSWIRE) — Global Diversified Marketing Group Inc (OTC: GDMK) reported results for its fiscal year ended December 31st, 2020.Financial highlights for the full year ended December 31st, 2020, compared to the full year ended December 31st, 2019, were as follows:Revenue increased to $1,660,726 compared to $1,317,092, an increase of 26.1% over 2019 periodGross profit margin improved to 39.8% in 2020 compared to 28.2% in 2019.  The net loss for the year ended December 31st, 2020, includes a one-time, non-cash, non-operating charge of $26,020,400 for stock-based compensation expense relating to the issuance of super-voting preferred stock to the Company’s Chief Executive Officer and $168,529 in stock-based compensation to consultants. Excluding those charges, the Company’s Adjusted Net Profit (Loss)...

Continue reading

Dolby Laboratories Chief Financial Officer Lewis Chew to Present at the Morgan Stanley 2021 Technology, Media, and Telecom Conference

SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) — Dolby Laboratories, Inc. (NYSE:DLB) today announced that Lewis Chew, Executive Vice President and Chief Financial Officer, Dolby Laboratories, will present at the Morgan Stanley 2021 Technology, Media, and Telecom Conference to be held virtually on Thursday, March 4, 2021, at 5:00 p.m. ET (2:00 p.m. PT).A live webcast and replay of the presentation will be available at http://investor.dolby.com.About Dolby LaboratoriesDolby Laboratories (NYSE: DLB) is based in San Francisco, California with offices around the globe. From movies and TV shows, to apps, music, sports and gaming, Dolby transforms the science of sight and sound into spectacular experiences for billions of people worldwide. We partner with artists, storytellers, developers, and businesses to revolutionize entertainment and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.